Management Considerations in Infective Endocarditis
Authors:
Top Cited Papers
- 3 July 2018
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 320 (1) , 72-83
Abstract
Importance Infective endocarditis occurs in approximately 15 of 100 000 people in the United States and has increased in incidence. Clinicians must make treatment decisions with respect to prophylaxis, surgical management, specific antibiotics, and the length of treatment in the setting of emerging, sometimes inconclusive clinical research findings. Observations Community–associated infective endocarditis remains the predominant form of the disease; however, health care accounts for one-third of cases in high-income countries. As medical interventions are increasingly performed on older patients, the disease incidence from cardiac implanted electronic devices is also increasing. In addition, younger patients involved with intravenous drug use has increased in the past decade and with it the proportion of US hospitalization has increased to more than 10%. These epidemiological factors have led toStaphylococcus aureusbeing the most common cause in high-income countries, accounting for up to 40% of cases. The mainstays of diagnosis are still echocardiography and blood cultures. Adjunctive imaging such as cardiac computed tomographic and nuclear imaging can improve the sensitivity for diagnosis when echocardiography is not conclusive. Serological studies, histopathology, and polymerase chain reaction assays have distinct roles in the diagnosis of infective endocarditis when blood culture have tested negative with the highest yield obtained from serological studies. Increasing antibiotic resistance, particularly toS aureus, has led to a need for different antibiotic treatment options such as newer antibiotics and combination therapy regimens. Surgery can confer a survival benefit to patients with major complications; however, the decision to pursue surgery must balance the risks and benefits of operations in these frequently high-risk patients. Conclusions and Relevance The epidemiology and management of infective endocarditis are continually changing. Guidelines provide specific recommendations about management; however, careful attention to individual patient characteristics, pathogen, and risk of sequela must be considered when making therapeutic decisions.Keywords
This publication has 118 references indexed in Scilit:
- HACEK Infective Endocarditis: Characteristics and Outcomes from a Large, Multi-National CohortPLOS ONE, 2013
- Infective Endocarditis in the U.S., 1998–2009: A Nationwide StudyPLOS ONE, 2013
- Successful Treatment of Vancomycin-Intermediate Staphylococcus aureus Pacemaker Lead Infective Endocarditis with TelavancinAntimicrobial Agents and Chemotherapy, 2010
- Update on Cardiovascular Implantable Electronic Device Infections and Their ManagementCirculation, 2010
- Clinical Presentation, Etiology, and Outcome of Infective Endocarditis in the 21st CenturyArchives of internal medicine (1960), 2009
- Addition of Rifampin to Standard Therapy for Treatment of Native Valve Infective Endocarditis Caused byStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2008
- Bacteremia Associated With Toothbrushing and Dental ExtractionCirculation, 2008
- Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused byStaphylococcus aureusNew England Journal of Medicine, 2006
- Staphylococcus aureus EndocarditisJAMA, 2005
- New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findingsThe American Journal of Medicine, 1994